PR Newswire: nyheter distribution, inriktning och uppföljning

'The Cell-Based Assays Market Will Reach $4.7 Billion in 2016' Shows New Visiongain Report

Share with Twitter Share with LinkedIn

LONDON, February 28, 2013 /PRNewswire/ --

A new report by visiongain predicts that the world market for cell-based assays will reach $4.7bn in 2016. That forecast and others appear in Cell-Based Assays: World Market Prospects 2013-2023, published in February 2013.

The new study explains how increased application and improvement in detection technology will be the major drivers for the cell-based assay market. As more pharma companies outsource drug discovery and development, forming strategic partnerships with contract research providers (CROs), cell-based assay services will increase their share of the market from 24.5% in 2011 to 30.2% in 2023, the report shows. In terms of application, primary screening accounted for the largest share of the cell-based assay market in 2011, with sales of $1.05bn (43.6%).

Hemant Mistry, a pharmaceutical industry analyst in visiongain, said: "Advances in detection equipment, improving sensitivity in drug screening, will act as key drivers for the cell-based assay market, in addition to the increased demand for more relevant and accurate toxicity models that can be used early in drug development. Miniaturising and multiplexing cell-based assays will make drug discovery more efficient and cheaper, which will also drive market growth over coming years.

"In 2011, developed markets - such as the US, Japan and Western Europe - accounted for the majority of the cell-based assays revenue. Global market shares for those countries are not expected to change significantly over the forecast period, as much of the world's drug discovery and development occurs there. The US accounted for 44.0% of the market in 2011. Emerging markets, such as China and India, will also experience strong growth throughout the period 2013-2023, we predict. Growth will be driven by increased outsourcing and also the trend of major pharmaceutical companies moving R&D there.

"There are strong opportunities for the cell-based assays market to expand in line with the continued development of technology for miniaturisation and automation, which includes higher sensitivity detection systems. Furthermore, the increased emphasis on stem cells will help develop disease-relevant models, as well as an abundant supply of unmodified human cells. Greater use of label-free detection systems will also allow the use of unmodified cells, removing the need to insert reporter proteins that can affect cell function. Opportunities will also arise from trends within the pharmaceutical industry, such as the need for more-accurate toxicity data before clinical trials, and the greater demand for biological drugs. Those drug classes will increase demand for immunogenicity, comparative and neutralising antibody assays."

Visiongain's report shows revenue forecasts to 2023 at world market, submarket and national level. It forecasts the following submarkets:

• Products
• Services.

That new study also analyses large CROs and other specialists in cell assaying products and services. Companies discussed include Covance, PPD, Charles River Laboratories, BD Biosciences and GE Healthcare.

The analysis explores technological trends. Also, it forecasts revenues in leading national markets: the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).

Cell-Based Assays: World Market Prospects 2013-2023 adds to visiongain's range of analytical reports on industries and markets for pharmaceutical technologies.


For sample pages and further information concerning the visiongain report Cell-Based Assays: World Market Prospects 2013-2023, please visit: http://www.visiongain.com/Report/988/Cell-Based-Assays-World-Market-Prospects-2013-2023

Companies Listed
Accuri Cytometers (now part of BD)
ACEA Biosciences
Active Biotech
Advinus Therapeutics
Agennix
Agilent Automation Solutions
American Type Culture Collection (ATCC)
Applied BioPhysics
Apredica (now part of Cyprotex)
AstraZeneca
Aurigene Discovery Technologies (a subsidiary of Dr Reddy's Laboratories)
Axiogenesis
BD Biosciences (a division of Becton, Dickinson & Co - BD)
Beckman Coulter (now part of Danaher)
Becton, Dickinson & Co.
BellBrook Labs
Bionas
Biopredic International
BioTek Instruments
BioTime
Boehringer Ingelheim
Boehringer Mannheim
Caliper Discovery Alliances and Services (CDAS, a subsidiary of Caliper Life Sciences)
Caliper Life Sciences (now part of PerkinElmer)
CellCyte Genetics
Cellomics (now part of Thermo Fisher Scientific)
Cellular Dynamics International
Cellumen
Charles River Laboratories
ChemBridge
ChemRar
Codex BioSolutions
Compugen
Corning Life Sciences
Cosmo Bio
Covance
Cubist Pharmaceuticals
Cyprotex
Cytogration
Danaher
Digilab
DiscoveRx
Dr. Reddy's Laboratories
EMD Millipore
Epistem
Eppendorf
European Collection of Cell Cultures (ECACC)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Evotec
Fluofarma
Food and Drug Administration (US FDA)
GE Healthcare (a division of General Electric)
Genentech
Genospectra
Geron
GSK
Hamilton Robotics
Harvard NeuroDiscovery Centre
Harvard University
HD Biosciences
HighRes Biosolutions
Hudson Robotics
IonGate
Jubilant Life Sciences
Labcyte
Leica Microsystems
Life Technologies
Lonza
Marin Biologic Laboratories
Matrical Bioscience
Maxim Biotech
MD Biosciences
MDS Analytical Technologies (now part of Danaher)
MedImmune
Merck KGaA
Midas Mediscience
Molecular Devices (a subsidiary of Danaher)
MultiCell Technologies
Novartis
NovaScreen Biosciences (part of Caliper Life Sciences)
Parexel International
PerkinElmer
Pfizer
PharmaGap
PPD
Promega
ProQinase
Proteome Sciences R&D
PsychoGenics
Puracyp
Q3DM (part of Beckman Coulter)
Quintiles
Radiometer (a subsidiary of Danaher)
ReachBio
Roche
Roche Applied Science (a division of Roche)
Seahorse Bioscience
Sentigen Holding (part of Life Technologies)
Shionogi & Company
Sigma-Aldrich
SRU Biosystems
Stem Cell Innovations
Stemgent
SymCel
Tata Group
Tecan
The Automation Partnership
Thermo Fisher Scientific
TTP LabTech
Tumour Biology Center Freiburg
UCB
University of Kyoto
University of Michigan
Veritas
Vitro Biopharma
World Trade Organization (WTO)
Xenogen Biosciences (formerly part of Caliper Life Sciences, acquired by Taconic in 2009) 


About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials and Automotive sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

SOURCE Visiongain



Journalister och bloggare

Besök PR Newswire för journalister för utsläpp, foton och anpassas matar bara för Media.

Visa och hämta arkiverade video Innehållet distribueras av MultiVu på Den digitala Center.

Share with Twitter Share with LinkedIn
 

Skapa innehåll för din webbplats

Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
börja idag.

 

 
 
 

Kontakta PR Newswire

Skicka oss ett mail till stockholm@prnewswire.se eller ring oss på +46 (0)8 1200 1300

 

 
 
 

Bli en PR Newswire kund

Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300

 

 
 
  1. Produkter & tjänster
  2. Pressmeddelanden
  3. Kontakta PR Newswire